VGX-3100 drives regression of HPV16/18 CIN2/3 and robust cellular immune responses in blood and cervical tissue in a blinded, randomized, placebo-controlled phase 2b study | Prakash Bhuyan | Inovio Pharmaceuticals, USA |

***** VGX-3100 drives regression of HPV16/18 CIN2/3 and robust cellular immune responses in blood and cervical tissue in a blinded, randomized, placebo-controlled phase 2b study | Prakash Bhuyan | Inovio Pharmaceuticals, USA | | Conferenceseries Ltd Cardiology Conference 2022|Cardiology Meet| Specific Cardio oncology Congress 2022| International Cardiology Conference| Dublin, Ireland Cardiology Conference 2022